NeuroMab™ Anti-TIM3 BBB Shuttle Antibody, Clone ABTIM3-hum11

Figure 1 shows that anti-TIM-3 monoclonal antibodies, including ABTIM3 and ABTIM3, bind the IgV domain, whereas 4A4 binds the mucin domain.

Shows that anti-TIM-3 mAb (anti-TIM-3 #3) and anti-PD-L1 control mAb (anti-PD-L1 #1 and #2) bind to the chimeric protein while anti-TIM-3 #2 Essentially does not bind to ABTIM3.

Figure 2 illustrates that the anti-TIM-3 antibodies anti-TIM-3 #2 and ABTIM3 block the binding of TIM-3 to PtdSer (phosphatidylserine).

Figure 3 illustrates that the anti-TIM-3 antibody ABTIM3 enhances IFN-γ secretion and proliferation in IL-12 stimulated CD4+ T cells.

Shown are the results of a representative experiment in which cells were exposed to antibody ABTIM3, anti-TIM-3 #2, mIgG1, and anti-PD-L1 control antibody (from left to right). IFN-γ levels were measured by flow cytometry.

Figure 4 shows that ABTIM3 blockade enhanced the in vitro cytotoxic activity of purified NK cells.

Figure 5 shows that the humanized anti-TIM-3 antibody competes for binding with the parental murine ABTIM3 antibody in a FACS assay.

Figure 6 illustrates the binding of humanized anti-TIM-3 antibodies to cells expressing human TIM-3.

Graph showing binding of humanized anti-TIM-3 antibodies to huTIM-3 expressing cells in a FACS assay. f

Figure 7 shows that ABTIM3-hum21 competes with ABTIM3-hum03 and ABTIM3-hum11 for binding to human TIM3, as determined by flow cytometry assays.

Figure 8 shows that ABTIM3 increases proliferation in co-cultures containing dendritic cells and T cells (DC-T co-culture). DC-T co-cultures were incubated with no antibody or a titration dilution series (0.01-25 µg/mL) of antibody mouse IgG1 (control), ABTIM3, or anti-TIM3 #3 antibody.

Figure 9 shows the concentration of ABTIM3-hum11 detected in serum over time in rodents. Inject the specified dose into mice or rats, and calculate the concentration of antibody in the blood at the specified time point.

Graph shows the mean serum concentration of BTIM3-hum11 in mice after antibody administration.

Figure 10 shows the concentration of ABTIM3-hum11 detected in serum over time in rodents. Inject the specified dose into mice or rats, and calculate the concentration of antibody in the blood at the specified time point.

Graph shows mean serum concentration of ABTIM3-hum11 in rats after antibody administration.

Figure 11 illustrates the binding of humanized anti-TIM-3 antibodies to cells expressing human TIM-3.

Graph showing competition of humanized anti-TIM-3 antibody with parental murine ABTIM3 for huTIM-3 expressing cells in a FACS assay.

Figure 12 illustrates that anti-TIM-3 antibody ABTIM3 enhances IFN-γ secretion and proliferation in IL-12 stimulated CD4+ T cells.

Graph quantifies IFN-γ expression in cells exposed to these four antibodies.

Figure 13 illustrates the binding and activity of various anti-TIM-3 antibodies.

Affinity of several anti-TIM-3 antibodies to cynomolgus monkey TIM-3 is shown. Among the antibodies tested in these experiments, the monoclonal antibody ABTIM3 had the highest affinity, indicating good cross-reactivity with both human and monkey targets.

Figure 14 illustrates the binding and activity of various anti-TIM-3 antibodies.

Binding curves of ABTIM3 and other anti-TIM-3 antibodies to cynomolgus TIM-3 are shown.